Proactive Investors - Run By Investors For Investors

Circassia Pharmaceuticals says partner AIT Therapeutics successfully completes FDA pre-submission meeting

The group said AIT anticipates submitting a Premarket Approval application for AirNOvent in the second quarter of 2019 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn
Circassia Pharmaceuticals says partner AIT Therapeutics successfully completes FDA pre-submission meeting
Circassia said it anticipates launching the product in the first half of 2020, once approved

Circassia Pharmaceuticals PLC (LON:CIR) revealed that its partner, AIT Therapeutics Inc. has successfully completed a pre-submission meeting with the US FDA for the ventilator-compatible nitric oxide product AirNOvent.

The AIM-listed specialty pharmaceutical company, which is focused on respiratory disease, said AIT anticipates submitting a Premarket Approval application (PMA) for AirNOvent in the second quarter of 2019 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN).

WATCH: Circassia's AirNOvent drug a step closer to market with FDA pre-submission meeting

Circassia said it anticipates launching the product in the first half of 2020, once approved.

The group announced on 24 January 2019 that it had entered a definitive agreement to acquire the exclusive commercialisation rights to AirNOvent in the United States and China from AIT. 

Under the agreement, the successful completion of the FDA meeting triggers a milestone payment of US$3.15mln, which Circassia said it intends to satisfy through the issuance of new ordinary shares in the company to AIT.

Steve Harris, Circassia's CEO, commented: "Successful completion of this pre-submission meeting represents a further key milestone in advancing AirNOvent towards the market. 

“We are excited at the potential benefits offered by AirNOvent, once approved, and look forward to AIT submitting this novel nitric oxide product for regulatory approval in the coming months."

View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

Related Articles

Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use